Investor Presentation Q1-Q3 2020

12 Investor presentation First nine months of 2020 Novo NordiskⓇ Biopharm sales growth of 4% driven by NorditropinⓇ and launches of new haemophilia products. Added reported Biopharm sales (YTD 2020 vs YTD 2019) DKK billion 4% -7% 0.8 0.6 0.4 0.2 0.0 -0.2 -0.4 -0.6 Growth at CER 1% Haemophilia 38% 13% I Biopharm sales driven by global commercial execution Biopharm sales growth driven by: 8% growth in International Operations NorditropinⓇ and launches of new haemophilia products Haemophilia sales decreased by 2% as: Successful EsperoctⓇ and Refixia® launches are countering the NovosevenⓇ sales decline NorditropinⓇ sales increased by 13% . Novo Nordisk is the leading company in the global human growth disorder market with a value market share of 35.3% Driven by new indications and global roll-out of the next generation device Novo- Total SevenⓇ Novo- Eight® Other haemo- philia® Nordi- tropin® YTD: Year-to-date Note: 'Other haemophilia' includes the new products EsperoctⓇ and RefixiaⓇ as well as NovoThirteenⓇ. Unless otherwise specified, sales growth is at constant exchange rates

View entire presentation